The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021
Open accessAbstract
Objective: To predict the global, regional, and national prevalence of Parkinson’s disease by age, sex, year, and Socio-demographic Index to 2050 and quantify the factors driving changes in Parkinson’s disease cases. Design: Modelling study. Data source: Global Burden of Disease Study 2021. Main outcome measures: Prevalent number, all age prevalence and age standardised prevalence of Parkinson’s disease in 2050, and average annual percentage change of prevalence from 2021 to 2050; contribution of population ageing, population growth, and changes in prevalence to the growth in Parkinson’s disease cases; population attributable fractions for modifiable factors. Results: 25.2 (95% uncertainty interval 21.7 to 30.1) million people were projected to be living with Parkinson’s disease worldwide in 2050, representing a 112% (95% uncertainty interval 71% to 152%) increase from 2021. Population ageing (89%) was predicted to be the primary contributor to the growth in cases from 2021 to 2050, followed by population growth (20%) and changes in prevalence (3%). The prevalence of Parkinson’s disease was forecasted to be 267 (230 to 320) cases per 100 000 in 2050, indicating a significant increase of 76% (56% to 125%) from 2021, whereas the age standardised prevalence was predicted to be 216 (168 to 281) per 100 000, with an increase of 55% (50% to 60%) from 2021. Countries in the middle fifth of Socio-demographic Index were projected to have the highest percentage increase in the all age prevalence (144%, 87% to 183%) and age standardised prevalence (91%, 82% to 101%) of Parkinson’s disease between 2021 and 2050. Among Global Burden of Disease regions, East Asia (10.9 (9.0 to 13.3) million) was projected to have the highest number of Parkinson’s disease cases in 2050, with western Sub-Saharan Africa (292%, 266% to 362%) experiencing the most significant increase from 2021. The ≥80 years age group was projected to have the greatest increase in the number of Parkinson’s disease cases (196%, 143% to 235%) from 2021 to 2050. The male-to-female ratios of age standardised prevalence of Parkinson’s disease were projected to increase from 1.46 in 2021 to 1.64 in 2050 globally. Conclusions: By 2050 Parkinson’s disease will have become a greater public health challenge for patients, their families, care givers, communities, and society. The upward trend is expected to be more pronounced among countries with middle Socio-demographic Index, in the Global Burden of Disease East Asia region, and among men. This projection could serve as an aid in promoting health research, informing policy decisions, and allocating resources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Self-citationNichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Ferrari, A. J., Santomauro, D. F., Aali, A., Abate, Y. H., Abbafati, C., Abbastabar, H., Abd ElHafeez, S., Abdelmasseh, M., Abd-Elsalam, S., Abdollahi, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00757-8 · Cited by 5,112
Self-citationAgeing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., Pletcher, M. A., Smith, A. E., Tang, K., Yuan, C.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31694-5 · Cited by 2,994
Dorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Worldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-H., Lv, J., Garg, A. X., Knight, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61601-9 · Cited by 2,339
Feigin, V. L., Abajobir, A. A., Abate, K. H., Abd-Allah, F., Abdulle, A. M., Abera, S. F., Abyu, G. Y., Ahmed, M. B., Aichour, A. N., Aichour, I., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30299-5 · Cited by 2,275
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Steinmetz, J. D., Seeher, K. M., Schiess, N., Nichols, E., Cao, B., Servili, C., Cavallera, V., Cousin, E., Hagins, H., Moberg, M. E., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00038-3 · Cited by 2,019
Self-citationFerreira, M. L., de Luca, K., Haile, L. M., Steinmetz, J. D., Culbreth, G. T., Cross, M., Kopec, J. A., Ferreira, P. H., Blyth, F. M., Buchbinder, R., et al. (2023) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00098-x · Cited by 1,877
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Vollset, S. E., Goren, E., Yuan, C.-W., Cao, J., Smith, A. E., Hsiao, T., Bisignano, C., Azhar, G. S., Castro, E., Chalek, J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30677-2 · Cited by 1,506
Facing up to the global challenges of ageing
Partridge, L., Deelen, J., & Slagboom, P. E. (2018) · Nature · doi:10.1038/s41586-018-0457-8 · Cited by 1,475
Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble
Kontis, V., Bennett, J. E., Mathers, C. D., Li, G., Foreman, K., & Ezzati, M. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32381-9 · Cited by 1,219
The Parkinson Pandemic—A Call to Action
Dorsey, E. R., & Bloem, B. R. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3299 · Cited by 1,091
Vollset, S. E., Ababneh, H. S., Abate, Y. H., Abbafati, C., Abbasgholizadeh, R., Abbasian, M., Abbastabar, H., Abd Al Magied, A. H. A., Abd ElHafeez, S., Abdelkader, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00685-8 · Cited by 1,025
Self-citationTran, K. B., Lang, J. J., Compton, K., Xu, R., Acheson, A. R., Henrikson, H. J., Kocarnik, J. M., Penberthy, L., Aali, A., Abbas, Q., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01438-6 · Cited by 954
Self-citationTai chi and postural stability in patients with Parkinson's disease
Li, F., Harmer, P., Fitzgerald, K., Eckstrom, E., Stock, R., Galver, J., Maddalozzo, G., & Batya, S. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107911 · Cited by 890 · cited 1×
“56-58 Furthermore, the focus should be not only on assisting individuals with Parkinson’s disease but also on implementing measures to alleviate the increasing burden faced by care givers.”
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 881
The Global Burden of Disease Study at 30 years
Murray, C. J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01990-1 · Cited by 856
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 778
Black, R. J., Cross, M., Haile, L. M., Culbreth, G. T., Steinmetz, J. D., Hagins, H., Kopec, J. A., Brooks, P. M., Woolf, A. D., Ong, K. L., et al. (2023) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00211-4 · Cited by 674
Schrag, A., Hovris, A., Morley, D., Quinn, N., & Jahanshahi, M. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.06.011 · Cited by 549
Long-term effects of exercise and physical therapy in people with Parkinson disease
Mak, M. K., Wong-Yu, I. S., Shen, X., & Chung, C. L. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.128 · Cited by 549
Sex differences in Parkinson’s disease
Gillies, G. E., Pienaar, I. S., Vohra, S., & Qamhawi, Z. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.02.002 · Cited by 489
Murray, C. J. L., Callender, C. S. K. H., Kulikoff, X. R., Srinivasan, V., Abate, D., Abate, K. H., Abay, S. M., Abbasi, N., Abbastabar, H., Abdela, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32278-5 · Cited by 484
Self-citationLong-term PM 2.5 Exposure and Neurological HospitalAdmissions in the Northeastern United States
Kioumourtzoglou, M.-A., Schwartz, J. D., Weisskopf, M. G., Melly, S. J., Wang, Y., Dominici, F., & Zanobetti, A. (2016) · Environmental Health Perspectives · doi:10.1289/ehp.1408973 · Cited by 466
Parkinson's disease and exposure to agricultural work and pesticide chemicals
Semchuk, K. M., Love, E. J., & Lee, R. G. (1992) · Neurology · doi:10.1212/wnl.42.7.1328 · Cited by 439
Reitsma, M. B., Flor, L. S., Mullany, E. C., Gupta, V., Hay, S. I., & Gakidou, E. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00102-x · Cited by 434
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Evolution of prodromal Parkinson’s disease and dementia with Lewy bodies: a prospective study
Fereshtehnejad, S.-M., Yao, C., Pelletier, A., Montplaisir, J. Y., Gagnon, J.-F., & Postuma, R. B. (2019) · Brain · doi:10.1093/brain/awz111 · Cited by 374
The effects of tobacco control policies on global smoking prevalence
Flor, L. S., Reitsma, M. B., Gupta, V., Ng, M., & Gakidou, E. (2021) · Nature Medicine · doi:10.1038/s41591-020-01210-8 · Cited by 299
Zhu, J., Cui, Y., Zhang, J., Yan, R., Su, D., Zhao, D., Wang, A., & Feng, T. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00094-1 · Cited by 299
Self-citationHaakenstad, A., Yearwood, J. A., Fullman, N., Bintz, C., Bienhoff, K., Weaver, M. R., Nandakumar, V., LeGrand, K. E., Knight, M., Abbafati, C., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00429-6 · Cited by 258
A general method of decomposing a difference between two rates into several components
Gupta, P. D. (1978) · Demography · doi:10.2307/2060493 · Cited by 225
Neurodegenerative disease: Brain windfall
Gammon, K. (2014) · Nature · doi:10.1038/nj7526-299a · Cited by 200
Biswas, A., Harbin, S., Irvin, E., Johnston, H., Begum, M., Tiong, M., Apedaile, D., Koehoorn, M., & Smith, P. (2021) · Current Environmental Health Reports · doi:10.1007/s40572-021-00330-8 · Cited by 196
Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade
Marras, C., Canning, C. G., & Goldman, S. M. (2019) · Movement Disorders · doi:10.1002/mds.27720 · Cited by 192
Fang, X., Han, D., Cheng, Q., Zhang, P., Zhao, C., Min, J., & Wang, F. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.2421 · Cited by 171
Projection of the prevalence of Parkinson's disease in the coming decades: Revisited
Rossi, A., Berger, K., Chen, H., Leslie, D., Mailman, R. B., & Huang, X. (2018) · Movement Disorders · doi:10.1002/mds.27063 · Cited by 170
Projected numbers of people with movement disorders in the years 2030 and 2050
Bach, J., Ziegler, U., Deuschl, G., Dodel, R., & Doblhammer‐Reiter, G. (2011) · Movement Disorders · doi:10.1002/mds.23878 · Cited by 164
Yan, D., Zhang, Y., Liu, L., Shi, N., & Yan, H. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.05.005 · Cited by 163
Statistical procedures for analyzing mental health services data
Elhai, J. D., Calhoun, P. S., & Ford, J. D. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.07.003 · Cited by 146
Prevalence of Parkinson's Disease: A Community‐Based Study in China
Qi, S., Yin, P., Wang, L., Qu, M., Kan, G. L., Zhang, H., Zhang, Q., Xiao, Y., Deng, Y., Dong, Z., et al. (2021) · Movement Disorders · doi:10.1002/mds.28762 · Cited by 137
Self-citationProjections of future life expectancy in China up to 2035: a modelling study
Bai, R., Liu, Y., Zhang, L., Dong, W., Bai, Z., & Zhou, M. (2023) · The Lancet Public Health · doi:10.1016/s2468-2667(22)00338-3 · Cited by 127
Self-citationShort-term air pollution exposure aggravates Parkinson’s disease in a population-based cohort
Lee, H., Myung, W., Kim, D. K., Kim, S. E., Kim, C. T., & Kim, H. (2017) · Scientific Reports · doi:10.1038/srep44741 · Cited by 114
Martínez‐Martín, P., Macaulay, D. S., Jalundhwala, Y. J., Mu, F., Ohashi, E., Marshall, T., & Sail, K. (2018) · Movement Disorders · doi:10.1002/mds.27579 · Cited by 108
Impact of dietary exposure to food contaminants on the risk of Parkinson's disease
Petersen, M. S., Halling, J., Bech, S., et al. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.03.001 · Cited by 105
Wanneveich, M., Moisan, F., Jacqmin-Gadda, H., Elbaz, A., & Joly, P. (2018) · Movement Disorders · doi:10.1002/mds.27447 · Cited by 101
Kirrane, E. F., Bowman, C., Davis, J. A., Hoppin, J. A., Blair, A., Chen, H., Patel, M. M., Sandler, D. P., Tanner, C. M., Vinikoor-Imler, L., et al. (2015) · Journal of Occupational & Environmental Medicine · doi:10.1097/jom.0000000000000451 · Cited by 100
Linares, C., Martínez‐Martín, P., Rodríguez‐Blázquez, C., Forjaz, M. J., Carmona, R., & Díaz, J. (2016) · Environment International · doi:10.1016/j.envint.2016.01.017 · Cited by 85
Circuit-specific gene therapy reverses core symptoms in a primate Parkinson’s disease model
Chen, Y., Hong, Z., Wang, J., Liu, K., Liu, J., Lin, J., Feng, S., Zhang, T., Shan, L., Liu, T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.10.004 · Cited by 80
Bourque, M., Dluzen, D. E., & Paolo, T. D. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.02.003 · Cited by 78
Unraveling Parkinson’s Disease Neurodegeneration: Does Aging Hold the Clues?
Coleman, C., & Martin, I. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223363 · Cited by 76
Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease
Bourque, M., Morissette, M., & Paolo, T. D. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.005 · Cited by 63
Kanthasamy, A., Jin, H., Charli, A., Anantharam, V., & Kanthasamy, A. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.01.001 · Cited by 61
Zheng, Z., Zhu, Z., Zhou, C., Cao, L., & Zhao, G. (2022) · Neuroepidemiology · doi:10.1159/000527372 · Cited by 60
Caregiver burden is increased in Parkinson’s disease with mild cognitive impairment (PD-MCI)
Jones, A. J., Kuijer, R. G., Livingston, L., Myall, D. J., Horne, K., MacAskill, M. R., Pitcher, T. L., Barrett, P. T., Anderson, T., & Dalrymple‐Alford, J. C. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0085-5 · Cited by 59
Challenges in the clinical advancement of cell therapies for Parkinson’s disease
Skidmore, S., & Barker, R. A. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00987-y · Cited by 59
Zhong, Q., & Zhu, F. (2022) · Neuroepidemiology · doi:10.1159/000524208 · Cited by 57
Shin, W.-Y., Kim, J., Lee, G., Choi, S., Kim, S. R., Hong, Y., & Park, S. M. (2020) · BMC Public Health · doi:10.1186/s12889-020-08503-0 · Cited by 54
Association of Parkinson’s disease with industry sectors: a French nationwide incidence study
Vlaar, T., Kab, S., Schwaab, Y., Fréry, N., Elbaz, A., & Moisan, F. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0399-3 · Cited by 50
Aravindan, A., Newell, M. E., & Halden, R. U. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.172838 · Cited by 47
Chen, F., Chen, S., Si, A., Luo, Y., Hu, W., Zhang, Y., & Ma, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.973310 · Cited by 42
Variations in gender ratios support the connection between smoking and Parkinson's disease
Morozova, N., O’Reilly, É. J., & Ascherio, A. (2008) · Movement Disorders · doi:10.1002/mds.22045 · Cited by 41
Portugal, B., Artaud, F., Degaey, I., Roze, E. F., Fournier, A., Severi, G., Canonico, M., Proust‐Lima, C., & Elbaz, A. (2023) · Neurology · doi:10.1212/wnl.0000000000207424 · Cited by 36
Faizan, M., Sarkar, A., & Singh, M. P. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101727 · Cited by 25
Valent, F., Devigili, G., Rinaldo, S., Zotto, S. D., Tullio, A., & Eleopra, R. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3273-x · Cited by 22
Physical activity and risk of Parkinson’s disease: an updated systematic review and meta-analysis
Jiang, Y., Zhang, S., Chen, Y., Wang, H., He, X., Bin, C., Fu, R., Wang, H., Zhu, H., Pan, M., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12672-y · Cited by 19
Disease Mapping With Generative Models
Wang, F., Wang, J., Gelfand, A. E., & Li, F. (2017) · The American Statistician · doi:10.1080/00031305.2017.1392358 · Cited by 9
Cited by
Ferritin in ferroptosis: implications for neurodegenerative diseases (Review)
Chen, W., Tian, H., Wei, R., Chen, X., & Jia, Y. (2026) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2026.5790 · Cited by 12
Ayala, D. A., Hall, G. M., Das, D., Tijerina, E., Villagran, L. L., Khan, Z., Paliwal, D., Anand, A., Rimer, M., & Srinivasan, R. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01713-x · Cited by 1
“Parkinson’s disease (PD) is the fastest growing neurological disorder (Dorsey et al. 2018; Su et al. 2025) with no known cure.”
Chan, L. M. L., Choi, E. P. H., Wayne, P. M., & Kwok, J. Y. Y. (2026) · Geriatric Nursing · doi:10.1016/j.gerinurse.2026.104172
Metadata
- Authors
- Su, D., Cui, Y., He, C., Yin, P., Bai, R., Zhu, J., Lam, J. S. T., Zhang, J., Yan, R., Zheng, X., Wu, J., Zhao, D., Wang, A., Zhou, M., & Feng, T.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2025-03-05
- Volume
- 388
- Pages
- e080952
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4408208852
- Cited by
- 611
- References
- 73
- FWCI
- 337.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.